HomeREGISTERREGISTERSITEMAPContact us
Home > Available Issues
Original Articles
Clinical Experience of Lomefloxacine (SC-47111, NY-198) in Treatment of Urinary Tract Infection
Soo Cheol Lee, Je Jong Kim, Sung Kum Koh
Department of Urology, Korea University College of Medicine Seoul, Korea
Vol.24 Num.1 (p37~43)
Lomefloxacine (SC-47111, NY-198), a new sythetic difluorinated quinolone for oral use with broad spectum antimicrobial activity, was administered in the treatment of 38 patients with urinary tract infection (uncomplicated 27, complicated 11). 154 cases of urine cultures including those of 38 patients treated by lomefloxacine were performed during the synchronous period. We reviewed the bacteriological, clinical effectiveness 문 side effects of Lomefloxacine.
The following results were obtained.
1) Among the 154 urine cultures with the growth of microorganism, 131 were sensitive to Lomefloxacine (overall sensitive rate; 85%) but the sensitive rates in Pseudomonas aeruginosa and Stereptococcus group D were 63% and 47% respectively.
2) In 27 uncomplicated urinary tract infection (UTI), 26 patients were cured and 1 patient was improved clinically in 5~9 days post treatment period. In 11 complicated UTI, 2 and 9 showed cure and improvement respectively.
3) In 39 isolated causative microorganism (E. coli 30, Staphylococcus epidermidis 2, E. aerogenes 2, Streptococcus group D 2, Pseudomonas aeruginosa 1, Morganella morganii 1, Proteus mirabilis 1), the total of 39 cases were eradicated.
4) There were not any significant side effects that required discontinuation of lomefloxacine during the treatment.
from the above results, lomefloxacine was considered to be a useful new oral antibiotic in the treatment of UTI without any significant side effects.
Keywords :